Pleural Mesothelioma
Primary Outcome Measures ORR [ Time Frame: 6 months after the final enrollment ] Objective Response Rate（ORR）according to mRECIST 1.1 standard Secondary Outcome Measures DOR [ Time Frame: 24 months ] Duration of remission DCR [ Time Frame: 24 months ] Disease Control Rate PFS [ Time Frame: 24 months ] Progression Free Survival OS [ Time Frame: 24 months ] Overall Survival AE [ Time Frame: 24 months ] Adverse event SAE [ Time Frame: 24 months ] Incidence and Severity of…
Researchers are looking into changing mesothelioma cells to make them more susceptible to immunotherapy. Mesothelioma is a hard cancer to treat, so new approaches need to be developed to try to lengthen and improve mesothelioma patients’ lives. Immunotherapy can work well for some, but for others it does very little, so researchers need to find…
The National Cancer Institute just started a study to see if it could make immunotherapy more potent for treating mesothelioma. The study combines a manmade protein that kills cancer cells called LMB-100 and an immunotherapy drug called ipilumab. The problem with current immunotherapy treatments is they do not work well with mesothelioma. The combination of…
An enzyme that helps clean up the byproducts of cellular oxidation could potentially be a biomarker for pleural mesothelioma. People with very small amounts of the enzyme were found to survive longer than people who have higher levels of the enzyme. The enzyme is Glutathione peroxidase-1 (GPX-1). It can be found in all cells to…
Studies are showing that the immunotherapy drug durvalumab can make chemotherapy more effective for treating mesothelioma. Durvalumab is an immunotherapy drug called an immune checkpoint inhibitor. It blocks the protein PD-1, which is used by mesothelioma cells to protect themselves. Researchers believed that if the protein was blocked, mesothelioma cells would be easier to kill…
A blood test for mesothelioma could help increase the time between CT scan appointments. The typical way doctors test to see if a treatment is working is called mRECIST, which utilizes CT scans and other measurements. CT scans are expensive though and can lead to larger exposure to ionizing radiation than someone might expect. The…
A chemical that makes cancer cells more sensitive to radiation could potentially help patients with mesothelioma. Radiotherapy utilizes ionizing radiation to damage the DNA of cancer cells, which affects their ability to reproduce and form tumors. Radiation is not always used for mesothelioma patients because mesothelioma cells can be immune to radiation and it can…
Researchers have potentially found a new way to treat cancer by targeting nerve cells. Researchers at Technion, the Israel Institute of Technology, conducted the study that is now published in the Science Advances journal. The research targets neurons, which promote tumor growth. The researchers assumed that once tumor nerve cells were targeted with a damaging…
Mesothelioma patients with a gene mutation could benefit greatly from using an anti-malaria drug called quinacrine. Quinacrine is known by the brand name Atabrine. For a long time, it was the primary anti-malaria drug, but it has been replaced by the preferred chloroquine. Researchers at Penn State found that quinacrine shows great cytotoxicity when used…
Combining the drug ramucirumab with the chemotherapy drug gemcitabine is showing to be a successful second line treatment for pleural mesothelioma. Ramucirumab is a type of immunotherapy drug called a monoclonal antibody, which targets and restricts proteins that stimulate blood vessel growth in tumors. The Lancet Oncology published the results of the Italian study involving…
